Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Retinal imaging

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44344   clinical trials with a EudraCT protocol, of which   7373   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    85 result(s) found for: Retinal imaging. Displaying page 1 of 5.
    1  2  3  4  5  Next»
    EudraCT Number: 2010-023900-29 Sponsor Protocol Number: MAF-AGN-OPH-RET-004 Start Date*: 2011-08-23
    Sponsor Name:Allergan Pharmaceuticals Ireland
    Full Title: A 12-Month, Multicentre, Randomised, Parallel Group Study to Compare the Efficacy and Safety of Ozurdex® Versus Lucentis® in Patients with Branch Retinal Vein Occlusion
    Medical condition: Macula oedema secondary to branch retinal vein occlusion
    Disease: Version SOC Term Classification Code Term Level
    17.0 10015919 - Eye disorders 10025415 Macular oedema PT
    17.0 10015919 - Eye disorders 10038907 Retinal vein occlusion PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2021-000183-29 Sponsor Protocol Number: REVISION Start Date*: 2022-03-09
    Sponsor Name:Eberhard-Karls University Tübingen, Med. Fac. rep. by University Hospital and its Commercial Director
    Full Title: Early Reperfusion Therapy with Intravenous Alteplase for Recovery of VISION in Acute Central Retinal Artery Occlusion (REVISION) - A double-blind randomized placebo-controlled phase III proof-of-co...
    Medical condition: Acute non-arteritic central retinal artery occlusion (CRAO)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10015919 - Eye disorders 10007971 Central retinal artery occlusion LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-001085-10 Sponsor Protocol Number: CRFB002AGB17 Start Date*: 2014-09-08
    Sponsor Name:Novartis Pharmaceuticals UK Ltd
    Full Title: A phase IV, prospective, open label, uncontrolled, European study in patients with neovascular age-related macular degeneration (nAMD), evaluating the efficacy and safety of switching from intravit...
    Medical condition: Visual impairment due to neovascular AMD
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004853 10060837 Choroidal neovascularization LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2018-003500-40 Sponsor Protocol Number: PQ-110-002 Start Date*: 2019-04-08
    Sponsor Name:ProQR Therapeutics IV B.V.
    Full Title: An Open-Label Extension Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetics of QR-110 in Subjects with Leber Congenital Amaurosis (LCA) due to the C.2991+1655a>G Mutation (P....
    Medical condition: Leber Congenital Amaurosis (LCA) due to c.2991+1655A>G Mutation (p.Cys998X) in the CEP290 Gene
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10070667 Leber's congenital amaurosis PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2019-000804-14 Sponsor Protocol Number: OPHT-070119 Start Date*: 2019-05-10
    Sponsor Name:Medical University of Vienna, Department of Clinical Pharmacology
    Full Title: The effect of hyperoxia and hypoxia on fluorescence lifetime imaging ophthalmoscopy in healthy subjects
    Medical condition: healthy volunteers
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-004547-77 Sponsor Protocol Number: RN03-CP-0001 Start Date*: 2020-06-09
    Sponsor Name:ReNeuron Ltd
    Full Title: First-in-human Phase I/IIa, Open-Label, Prospective Study of the Safety and Tolerability of Subretinally Transplanted Human Retinal Progenitor Cells (hRPC) in Subjects with Retinitis Pigmentosa (RP)
    Medical condition: Retinitis Pigmentosa
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10038914 Retinitis pigmentosa PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2020-000535-45 Sponsor Protocol Number: PQ-110-005 Start Date*: 2020-11-13
    Sponsor Name:ProQR Therapeutics IV B.V.
    Full Title: An Open-Label, Dose Escalation and Double-Masked, Randomized, Controlled Study to Evaluate the Safety and Tolerability of Sepofarsen in Pediatric Subjects <8 Years of Age with Leber Congenital Amau...
    Medical condition: Leber Congenital Amaurosis 10 (LCA10) due to c.2991+1655A>G mutation (p.Cys998X) in the CEP290 Gene
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10070667 Leber's congenital amaurosis PT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) GB (GB - no longer in EU/EEA) NL (Ongoing) IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-000813-22 Sponsor Protocol Number: PQ-110-001 Start Date*: 2017-06-19
    Sponsor Name:ProQR Therapeutics
    Full Title: An Open-Label, Single Arm, Multiple Dose, Dose Escalation Study to Evaluate the Safety and Tolerability of QR-110 in Subjects with Leber’s Congenital Amaurosis (LCA) due to c.2991+1655A>G Mutation ...
    Medical condition: Leber’s Congenital Amaurosis (LCA) due to c.2991+1655A>G Mutation (p.Cys998X) in the CEP290 Gene
    Disease: Version SOC Term Classification Code Term Level
    19.1 10010331 - Congenital, familial and genetic disorders 10070667 Leber's congenital amaurosis PT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2015-001961-20 Sponsor Protocol Number: FYB201-C2015-01-P3 Start Date*: 2015-11-24
    Sponsor Name:Bioeq GmbH
    Full Title: Efficacy and safety of the biosimilar ranibizumab FYB201 in comparison to Lucentis in patients with neovascular age-related macular degeneration (COLUMBUS-AMD)
    Medical condition: Subfoveal neovascular age-related macular degeneration
    Disease: Version SOC Term Classification Code Term Level
    20.0 10015919 - Eye disorders 10071129 Neovascular age-related macular degeneration PT
    20.0 100000116602 10067791 Wet macular degeneration LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) AT (Completed) DE (Completed) HU (Completed) ES (Completed) FR (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-000379-41 Sponsor Protocol Number: RLBUHT3407 Start Date*: 2007-05-22
    Sponsor Name:Royal Liverpool & Broadgreen University hospital
    Full Title: Liverpool Avastin Dose Response and Retreatment Study
    Medical condition: Exudative senile macular degeneration of the retina
    Disease: Version SOC Term Classification Code Term Level
    9.1 10015902 Exudative senile macular degeneration of retina LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-003556-31 Sponsor Protocol Number: SHP-607-201 Start Date*: 2015-02-10
    Sponsor Name:Premacure AB, A Member of the Shire Group of Companies
    Full Title: Long-term Outcome of Children Enrolled in Study ROPP-2008-01 Previously Treated with rhIGF-1/rhIGFBP-3 for the Prevention of Retinopathy of Prematurity (ROP) or Who Received Standard Neonatal Care
    Medical condition: Retinopathy of Prematurity (ROP)
    Disease:
    Population Age: Newborns, Under 18 Gender: Male, Female
    Trial protocol: SE (Completed) GB (GB - no longer in EU/EEA) NL (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-000781-38 Sponsor Protocol Number: sempa1 Start Date*: 2019-05-07
    Sponsor Name:Aarhus University Hospital
    Full Title: Effect of Empagliflozin and Semaglutide on Cardio-Renal Target Organ Damage in patients with type 2 diabetes – A randomized Trial
    Medical condition: Type 2 Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004861 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2014-001351-23 Sponsor Protocol Number: EGT022-01 Start Date*: 2017-08-15
    Sponsor Name:EyeGene, Inc
    Full Title: A phase IIa, randomized, placebo-controlled, double-blind, parallel study to investigate the efficacy of EG-Mirotin subcutaneously administered in multiple doses on diabetic macular edema in diabet...
    Medical condition: diabetic retinopathy patients having early diabetic macular edema (DME)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10015919 - Eye disorders 10012689 Diabetic retinopathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2018-003501-25 Sponsor Protocol Number: PQ-110-003 Start Date*: 2019-02-28
    Sponsor Name:ProQR Therapeutics IV B.V.
    Full Title: A Double-Masked, Randomized, Controlled, Multiple-Dose Study to Evaluate the Efficacy, Safety, Tolerability and Systemic Exposure of QR-110 in Subjects with Leber’s Congenital Amaurosis (LCA) due t...
    Medical condition: Leber’s Congenital Amaurosis (LCA) due to c.2991+1655A>G Mutation (p.Cys998X) in the CEP290 Gene
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10070667 Leber's congenital amaurosis PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed) NL (Ongoing) BE (Completed) FR (Ongoing) GB (GB - no longer in EU/EEA) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-004169-14 Sponsor Protocol Number: BMS-MB102-210 Start Date*: 2014-02-07
    Sponsor Name:University Hospital Erlangen
    Full Title: Randomized, placebo controlled, crossover clinical study to analyse the effect of dapagliflozin on microvascular and macrovascular circulation and total body sodium content
    Medical condition: Type 2 diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004861 10012613 Diabetes mellitus non-insulin-dependent LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2020-002452-20 Sponsor Protocol Number: CRTH258AIT04 Start Date*: 2021-01-13
    Sponsor Name:NOVARTIS FARMA S.P.A.
    Full Title: One year, single arm, open label, multicenter, phase IV study using multimodal imaging to guide disease activity assessment through innovative early predictive anatomical biomarkers of fluid resolu...
    Medical condition: Age-related neovascular macular degeneration
    Disease: Version SOC Term Classification Code Term Level
    20.0 10015919 - Eye disorders 10071129 Neovascular age-related macular degeneration PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-003193-14 Sponsor Protocol Number: DIAMOND Start Date*: 2017-10-03
    Sponsor Name:Department of Ophthalmology, MUW
    Full Title: Disease-modification under treatment with aflibercept in advanced diabetic retinopathy - A pilot study
    Medical condition: proliferative diabetic retinopathy
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-004844-35 Sponsor Protocol Number: TG-MV-005 Start Date*: 2009-07-01
    Sponsor Name:ThromboGenics NV
    Full Title: A randomized, sham-injection controlled, double-masked, multicenter trial of microplasmin intravitreal injection for treatment of exudative age-related macular degeneration (AMD).
    Medical condition: Patients with exudative AMD with focal vitreomacular adhesion
    Disease: Version SOC Term Classification Code Term Level
    9.1 10015902 Exudative senile macular degeneration of retina LLT
    9.1 10051065 Vitreomacular traction syndrome LLT
    9.1 10060823 Choroidal neovascularisation PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) GB (Completed) DE (Completed) IT (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2013-003320-36 Sponsor Protocol Number: 190342-038 Start Date*: 2015-03-02
    Sponsor Name:Allergan Limited
    Full Title: Safety and Efficacy of Brimonidine Posterior Segment Drug Delivery System in Patients with Geographic Atrophy Secondary to Age-related Macular Degeneration (BEACON Study)
    Medical condition: Geographic Atrophy Secondary to Age-related Macular Degeneration
    Disease: Version SOC Term Classification Code Term Level
    20.0 10015919 - Eye disorders 10025409 Macular degeneration PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-002431-30 Sponsor Protocol Number: GT005-03 Start Date*: 2020-10-21
    Sponsor Name:Gyroscope Therapeutics
    Full Title: HORIZON: A Phase II, open-label, outcomes-assessor masked, multicentre, randomised,controlled study to evaluate the safety and efficacy of two doses of GT005 administered as a single subretinal inj...
    Medical condition: Age-related Macular Degeneration (AMD) presents as a progressive loss of vision in the centre of the retina (the macula) resulting in a blurred area or blank spot in the centre of vision. The prima...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004853 10075719 Atrophic age-related macular degeneration LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) FR (Completed) IE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Jun 20 06:12:10 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA